FDA Approves Unknown Drug — AMNEAL PHARMS CO

AMNEAL PHARMS CO. announced the FDA approval of its ANDA submission [Substance], broadening its product portfolio with a potential new entrant in the healthcare space that is expected to provide incremental revenue streams; however, as the approval was secured in 2019, the long-term market impact is likely minimal relative to current valuation metrics.